ENTERA BIO LTD. Current Liabilities
ENTERA BIO LTD. (ENTX) had Current Liabilities of $2.10 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-07
- 2026-06-30: Liabilities, Current $2.10M.
- 2026-03-31: Liabilities, Current $1.58M.
- 2025-12-31: Liabilities, Current $2.20M.
- 2025-09-30: Liabilities, Current $1.57M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $2.10M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.58M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $2.20M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $1.57M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.84M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $1.62M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $1.18M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.11M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $1.29M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $1.12M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $1.09M 10-K · filed 2025-03-28 |
| 2023-09-30 | $2.03M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.86M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $1.49M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $1.34M 10-K · filed 2024-03-08 |
| 2022-09-30 | $1.19M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.69M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.33M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.16M 10-K · filed 2023-03-31 |
| 2020-12-31 | $1.84M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |